Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis

<p><b>Article full text</b></p><p><br></p><p>The full text of this article can be found here<b>.</b> <a href="https://link.springer.com/article/10.1007/s40744-018-0097-3">https://link.springer.com/article/10.1007/s40744-018-0097-3</a></p><p></p><p><br></p><p><b>Provide enhanced content for this article</b></p><p><br></p><p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p><p><br></p><p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include, but are not limited to:</p><p><br></p><p>• Slide decks</p><p>• Videos and animations</p><p>• Audio abstracts</p><p> </p><p>• Audio slides</p> <p> </p

Additional file 1: Table S1. of Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Glossary. Description of data: Glossary of vaccination terminology. (DOCX 28 kb

Additional file 4: Table S4. of Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Geometric mean titers and immunologic response to individual antigens 28 days post-vaccination. Description of data: Pre-and post-vaccination geometric mean titers and immunologic responses are shown for individual pneumococcal and influenza vaccine antigens in the total patient population. (DOCX 29 kb

Additional file 2: Table S2. of Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Relationship of baseline factors with pneumococcal and influenza immunologic responses stratified by age (<55 or ≥55 years). Description of data: Pneumococcal and influenza vaccine responses are shown for patients <55 and ≥55 years according to baseline factors. (DOCX 29 kb

Additional file 3: Table S3. of Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Geometric mean titers and immunologic response to individual antigens 28 dayspost-vaccination. Description of data: Pre-and post-vaccination geometric mean titers and immunologic responses are shown for individual pneumococcal and influenza vaccine antigens in patients without protective antibody levels at baseline. (DOCX 29 kb

Western blot analysis of YKL-40 in the lysate and conditioned media from undifferentiated MSCs.

<p><b>A.</b> Western blot analysis using a primary anti-YKL-40 polyclonal antibody of a gel containing a positive YKL-40 control (conditioned media from MG-63 osteosarcoma cells), MSC media alone, cell lysate from undifferentiated MSCs, and conditioned media from undifferentiated MSCs. No YKL-40 protein was detected in either the MSC cell lysate or MSC conditioned media. <b>B.</b> Western blot of cell lysates from undifferentiated MSCs treated with 10 µM of the proteasome inhibitor MG132 for 1, 2, 4, and 6 hours. Controls include DMSO alone (equivalent to that in the MG132 stock solution) and MG-63 conditioned media as a positive control for YKL-40.</p

Western Blot analysis of YKL-40 in cell lysate and media supernatant of MSCs differentiated using neuron protocol 2 (using ß-mercaptoethanol).

<p>Lane 1, cell lysate. Lane 2, conditioned media from trans-differentiated cell cultures.</p

Screening RT-PCR analysis of transcribed mRNAs in undifferentiated MSCs.

<p>Total RNA was isolated from undifferentiated mesenchymal stem cells cultured in tissue culture plates using Trizol. Following reverse transcription using random hexamer primers, the resulting cDNAs were amplified in a series of PCR reactions using primers for YKL-40 and other members of the human chitinase family, as well as primers for two control mRNAs (beta actin and GAPDH), the cytokine MIF, and the NF-kB inhibitor IkB (primer sequences shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062491#pone-0062491-t001" target="_blank">Table 1</a>). PCR reaction products were separated using agarose gel electrophoresis and visualized using EtBr and UV light.</p

Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>.</b> <a href="https://link.springer.com/article/10.1007/s40744-018-0093-7">https://link.springer.com/article/10.1007/s40744-018-0093-7</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

Additional file 1: of A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Supplementary methods and results, supplementary figures and figure legends, and supplementary tables. (PDF 394 kb